PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

BACKGROUND: Recurrent, platin-resistant ovarian cancer (rPROC) has a poor survival. Even with the AURELIA trial, which is the best available treatment today, progression-free survival (PFS) is still only 6.7 months from the start of the second-line chemotherapy. Innovative, effective therapies are u...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakrin, Naoual, Tempfer, Clemens, Scambia, Giovanni, De Simone, Michele, Gabriel, Boris, Grischke, Eva-Maria, Rau, Beate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405004/
https://www.ncbi.nlm.nih.gov/pubmed/30911662
http://dx.doi.org/10.1515/pp-2018-0114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405004/
https://www.ncbi.nlm.nih.gov/pubmed/30911662
http://dx.doi.org/10.1515/pp-2018-0114

Ejemplares similares